Why the study?
Does the combined use of ACE inhibitors and aspirin affect clinical outcomes or hemodynamic parameters in patients with congestive heart failure?
Does the combined use of ACE inhibitors and aspirin affect clinical outcomes or hemodynamic parameters in patients with congestive heart failure?
There is currently a lack of prospective data on the clinical outcomes of combining ACE inhibitors and aspirin in CHF patients, highlighting the need for ongoing trials to determine their combined efficacy.
Answers are grounded in this paper and cite their sources.
Absence of prospective outcome data limits confident combined use of aspirin and ACE inhibitors in CHF; leaves open the need for trials on clinical endpoints.
OBJECTIVE: To review the literature evaluating the interaction between angiotensin-converting enzyme (ACE) inhibitors and aspirin in patients with congestive heart failure (CHF). DATA SOURCES: A literature search through MEDLINE (1966-March 2001) and EMBASE (1966-March 2001) identified randomized, double-blind, controlled trials evaluating the use of ACE inhibitors and aspirin in patients with CHF. DATA SYNTHESIS: No prospective study has evaluated the effects of aspirin and ACE inhibitors on clinical outcomes of patients with CHF. All have been short-term studies evaluating the effects on hemodynamic parameters only. CONCLUSIONS: While the potential for an interaction between ACE inhibitors and aspirin exists, the results from ongoing prospective trials will help determine the efficacy of using both agents in patients with CHF.
No takes yet. Share an insight, caveat, or question.
Kari L. Olson (2001) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: